Bacopa herb

Free to every reader. The safety section of every monograph is open to everyone, signed in or not. In an emergency call 000. For poisoning, call the Poisons Information Centre on 13 11 26.

15. Safety

Adverse effects in trials. Mild gastrointestinal effects (nausea, increased stool frequency, diarrhoea, abdominal cramps) are the consistent finding: "a few incidences" in most of the pooled trials, "predominantly seen in the B. monnieri groups as opposed to the placebo", and two trials gave no side-effect detail [35]. In the Calabrese trial there were 18 adverse events on bacopa and 23 on placebo; 9 and 10 respectively were judged possibly related, most often "flu-like symptoms" and "digestive problems" [24]; a review of trials in older adults found adverse events reported in both placebo and active arms [30]. One participant stopped bacopa for a perioral maculopapular rash that began in week 8 and lasted about 15 days [25]. Serum calcium rose within the normal range in one student trial [23]. Causality for the rash is possible (single event, no rechallenge). No serious adverse event attributed to bacopa was reported in the trials read.

Case reports and pharmacovigilance. No case report was found in the sources read. A search of the TGA website for "bacopa" in September 2026 returned 140 items: ARTG entries, sponsor cancellations, one guidance page and one listed-medicine compliance report, and no safety alert, safety update or recall [51]. The compliance report (MediHerb Bacopa Complex (N/F), review outcome 21/02/2022) concerned safrole in the product’s rosemary oil, not bacopa; later testing put safrole within limits, the TGA said it was safe to continue using the medicine, and the sponsor cancelled the product [52]. The TGA Database of Adverse Event Notifications (medicines) is now an interactive report behind a terms page and could not be queried by automated means in September 2026; a manual search is outstanding (section 18), so no statement is made here about DAEN reports.

Toxicology. A Thai ethanol extract (6.25 per cent saponins) caused no toxicity in rats at a single 5,000 mg/kg dose or at 30–1,500 mg/kg a day for 270 days, on clinical chemistry, haematology and histopathology [32]. The oral LD50 of an ethanolic extract is reported as 17 g/kg, a figure Braun and Cohen take from Mills and Bone (2005) [8, p. 143] and Calabrese and colleagues give for an alcoholic extract, with no toxicity from a water extract at up to 5 g/kg in rats [24]; neither primary source was read. Phase I studies of a dried water extract in healthy men, up to 450 mg a day for 4 and 6 weeks, are reported without safety concerns [24]; the primary papers are on order. Reversible suppression of spermatogenesis and fertility in male mice is reported by Gościniak and colleagues [33]; the primary paper is on order, and the doses have not been assessed here (animal evidence only). On body-surface scaling the 270-day rat dose is about 28 times the top trial dose (Figure 13).

Contraindications and cautions.

• Hyperthyroidism: caution, because a leaf extract (200 mg/kg) raised serum T4 by 41 per cent in male mice [8, p. 143; 33]. Grade: animal evidence only (Tier P); the caution itself is a practitioner-text position [8]. AIP comment: the same finding is a reason to watch thyroid function when bacopa is given with thyroxine or antithyroid drugs [33].
• Pregnancy: no human data. Braun and Cohen record "insufficient reliable information available" [8, p. 143]; Gościniak and colleagues find no clinical studies and no animal study that addresses safety in pregnancy [33]. Grade: no evidence either way. MediHerb advises professional supervision [7, pp. 26, 102–103]. AIP view: avoid unless a degree-qualified herbalist judges the benefit clear.
• Lactation: no human data and no study of transfer into breast milk [33]; Braun and Cohen do not address lactation [8]. Grade: no evidence either way. MediHerb advises professional supervision [7]. AIP view: as for pregnancy.
• Male fertility: reversible antispermatogenic effect in male mice [33]. Grade: animal evidence only (Tier P). AIP comment: worth raising with men who are trying to conceive.
• Surgery: MediHerb advises stopping 7 days before general anaesthesia [7, p. 26]. The guide prints the same sentence on many of its herb pages (baical skullcap, for one), so it is a general manufacturer precaution; no mechanism or case specific to bacopa is given.

Herb–drug interactions (graded as clinical, pharmacokinetic study or theoretical; no bacopa interaction reaches the first two).

No pharmacokinetic interaction study in humans was found.

Children and older people. In the trial in children aged 7–12, the beverage of bacopa extract with micronutrients was well tolerated, with no treatment-related or serious adverse events [27]. The open-label ADHD series in children aged 6–12 is known here only through a review that gives no safety data for it [31]. A 2025 review reports a few short-lived cases of gastrointestinal discomfort, none leading to withdrawal, in two ADHD trials in children aged 6–14, and gastrointestinal disturbances including vomiting and upset stomach lasting about three days in two trials in children aged 4–18 and 6–12 [33]; those primary papers were not read. Trials in adults over 65 reported adverse events similar to placebo [24,30]. The Permissible Ingredients Determination sets no specific requirements for this ingredient, so no ingredient-specific label warning is required [9].

Overdose. No human overdose report was found in the sources read or on the TGA website.

Contaminant risk. Heavy-metal accumulation (section 10) is the main quality-related safety risk for a wetland plant.

Referral. Anyone thinking of using bacopa while pregnant, breastfeeding, trying to conceive, taking thyroid medicine, a cholinesterase inhibitor or a drug with a narrow margin cleared by CYP3A4 or CYP2C9 should consult a degree-qualified herbalist with competencies and adequate training in pharmacognosy.